中源协和：部分募集资金投资项目延期

Core Viewpoint - The company announced a delay in the clinical trial progress of its "Tumor Biomarker Diagnostic Reagent Development Project" due to public health events and new clinical trial guidelines, pushing the project completion date to December 2026 [1] Investment Project Details - The planned investment amount for the project is 60 million yuan, funded by raised matching funds [1] - The project focuses on the development of diagnostic kits for gene mutation testing, specifically targeting genes such as EGFR, KRAS, BRAF, NRAS, ERBB2, and PIK3CA, as well as a multi-gene mutation testing kit for circulating tumor DNA [1] Impact of Delay - The delay does not involve changes to the implementation entity, method, or investment amount, and it will not affect the direction of the raised funds [1] - The company asserts that the delay will not have a substantial impact on its normal operations [1]